Q-omics provides the consensus-scored RPL15 profile across patient tissues and cancer cell-line models. RPL15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL15 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, RPL15 protein abundance shows 21,256 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, LIHC, and BRCA as cancer lineages where RPL15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL15 survival associations across molecular data types. RPL15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL15 RNA expression–survival associations across cancer types. High RPL15 expression shows unfavorable associations in ACC, LIHC and SARC, but favorable associations in UVM, LGG and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL15 RNA expression.
This table summarizes RPL15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL15 shows lower tumor expression in HNSC, LUSC, BLCA, UCEC and LUAD and higher tumor expression in LIHC. The LIHC box plot shows higher RPL15 RNA expression in tumor versus normal tissue (log2 FC = +0.924, t-test p < 0.001).
This table shows molecular features associated with RPL15 in patient tissues and cancer cell lines. In patient samples, RPL15 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
